Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. BMJ Publishing Group.
Chicago Style (17th ed.) CitationCorrection: Systematic Preclinical Evaluation of CD33-directed Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia Defines Optimized Construct Design. BMJ Publishing Group.
MLA (9th ed.) CitationCorrection: Systematic Preclinical Evaluation of CD33-directed Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia Defines Optimized Construct Design. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.